Efficacy of Rifaximin, a Nonabsorbed Oral Antibiotic, in the Treatment of Small Intestinal Bacterial Overgrowth
- 31 May 2007
- journal article
- clinical trial
- Published by Elsevier BV in The American Journal of the Medical Sciences
- Vol. 333 (5), 266-270
- https://doi.org/10.1097/maj.0b013e3180536784
Abstract
Rifamixin is an orally administrated, nonabsorbed antibiotic whose utility in eradication of small intestinal bacterial overgrowth (SIBO) is currently being evaluated. The aim of this study was to investigate efficacy and safety of rifaximin in relieving symptoms and normalizing the glucose breath test (GBT) in patients with SIBO. Symptom score assessment, consisting of frequency and severity of bloating, gas, abdominal pain, and bowel movements and the GBT were performed before and after treatment with rifaximin 800 mg/d for 4 weeks. Twenty consecutive symptomatic patients (16 women and 4 men; mean age, 47.8 years; range, 19 to 85 years) who had a positive GBT were prospectively studied in an open-labeled fashion. Fourteen patients (70.0%) presented with diarrhea, 3 (15.0%) with bloating and gas, and 3 (15.0%) with constipation as the dominant symptom. Eleven patients were hydrogen producers, 8 exclusively methane, and 1 patient produced both gases by the GBT. Among patients with diarrhea, 12 of 14 (85.7%) reported improvement in symptom scores of more than 50%; 1 between 25% and 50%, 1 had no response after 4 weeks of rifamixin. Among patients with bloating and gas or constipation as the main symptom: 2 of 6 (33.3%) had improvement between 50% and 75%; 3 (50%) had 25% to 50% improvement, and 1 (16.7%) had no response. Repeat GBT at the end of the 4 weeks showed that 54.5% of hydrogen formers and 50.0% of methane producers were eradicated, and there was a significant reduction (P <0.05) in the area under the concentration-time curve and peak values. No adverse effects were observed. Rifaximin in a dose of 800 mg per day for 4 weeks: 1) was safe and effective treatment in reducing symptoms in patients with SIBO of multiple etiologies, especially when diarrhea was the dominant symptom; and 2) normalized the GBT in approximately 50% of patients. Data support a future therapeutic role for rifaximin in SIBO.Keywords
This publication has 15 references indexed in Scilit:
- The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel SyndromeAnnals of Internal Medicine, 2006
- Small Intestinal Bacterial Overgrowth: Roles of Antibiotics, Prebiotics, and ProbioticsGastroenterology, 2006
- Klinisch relevante Atemtests in der gastroenterologischen Diagnostik - Empfehlungen der Deutschen Gesellschaft für Neurogastroenterologie und Motilität sowie der Deutschen Gesellschaft für Verdauungs- und StoffwechselerkrankungenZeitschrift für Gastroenterologie, 2005
- Carbohydrate bioavailabilityBritish Journal of Nutrition, 2005
- Rifaximin dose‐finding study for the treatment of small intestinal bacterial overgrowthAlimentary Pharmacology & Therapeutics, 2005
- Rifaximin versus chlortetracycline in the short‐term treatment of small intestinal bacterial overgrowthAlimentary Pharmacology & Therapeutics, 2000
- Effect of Rifaximin on Intestinal Bacterial Overgrowth in Crohn's Disease as Assessed by the H2-Glucose Breath TestCurrent Medical Research and Opinion, 2000
- Intestinal Bacterial Overgrowth During Chronic PancreatitisCurrent Medical Research and Opinion, 1999
- Detection of malabsorption of low doses of carbohydrate: Accuracy of various breath H2 criteriaGastroenterology, 1993
- Breath Tests in the Diagnosis of Small Intestine Bacterial OvergrowthCRC Critical Reviews in Clinical Laboratory Sciences, 1984